Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Audio By Carbonatix

SAN DIEGO--(BUSINESS WIRE)--Mar 3, 2025--

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11 th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression. For more information, please visit www.contineum-tx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250303275278/en/

CONTACT: Steve Kunszabo

Contineum Therapeutics

Senior Director, Investor Relations & Corporate Communications

858-649-1158

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH NEUROLOGY

SOURCE: Contineum Therapeutics, Inc.

Copyright Business Wire 2025.

PUB: 03/03/2025 04:05 PM/DISC: 03/03/2025 04:06 PM

http://www.businesswire.com/news/home/20250303275278/en